What is CinCor Pharma, Inc. (CINC) stock price today?

CinCor Pharma, Inc. (CINC) is currently trading at $29.06, up 0% today.

What is CINC P/E ratio?

CinCor Pharma, Inc.'s P/E ratio is -20.46. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CINC return on equity (ROE)?

CinCor Pharma, Inc.'s return on equity (ROE) is 110.68%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is CinCor Pharma, Inc.'s market cap?

CinCor Pharma, Inc. has a market capitalization of $1.27B.

NASDAQ · Biotechnology

CinCor Pharma, Inc. (CINC) Stock

$29.06 +0.00% NASDAQ: CINC Healthcare

CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions.

Valuation

Metric	Value
Price	$29.06
Market Cap	$1.27B
P/E Ratio	-20.46
P/B Ratio	-16.15
P/S Ratio	0.00
EPS (TTM)	$-1.42
52-Week High	$43.15
52-Week Low	$10.53
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	110.68%
ROA	-35.68%
ROCE	-34.13%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	8.53

Annual Financials (USD)

Metric	2019	2020	2021
Revenue	$0	$0	$0
Operating Profit	$-5.0M	$-21.0M	$-43.0M
Net Profit	$-5.0M	$-22.0M	$-50.0M
EPS	$-0.21	$-0.95	$-1.42
Op Margin	—	—	—

Balance Sheet (USD)

Metric	2019	2020	2021
Total Assets	$12.0M	$27.0M	$141.0M
Total Liabilities	$17.0M	$54.0M	$205.0M
Cash	$11.0M	$26.0M	$137.0M
Borrowings	$0	$0	$0

Latest News

5 Insurance Stocks Poised to Outperform Q2 Earnings Expectations Zacks · Jul 22, 2026 Seeking Clues to Cincinnati Financial (CINF) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics Zacks · Jul 22, 2026 CINF: Raising target price to $199.00 Argus Research · Jul 22, 2026 Analysts Estimate Arch Capital Group (ACGL) to Report a Decline in Earnings: What to Look Out for Zacks · Jul 21, 2026 Cincinnati Financial (CINF) Is Up 0.84% in One Week: What You Should Know Zacks · Jul 20, 2026

Cash Flow (USD)

Metric	2019	2020	2021
Operating Cash Flow	$-4.0M	$-17.0M	$-31.0M
Investing Cash Flow	$0	$0	$0
Financing Cash Flow	$16.0M	$32.0M	$141.0M
Net Cash Flow	$11.0M	$15.0M	$111.0M
Free Cash Flow	$-4.0M	$-17.0M	$-31.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.23
EV / EBITDA	-32.78
FCF Yield	-2.43%
Quick Ratio	8.53
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALBOAlbireo Pharma, Inc.	$44.15	+0.00%	-5.61	$915.89M	0.00%
CTICCTI BioPharma Corp.	$9.10	+0.06%	-11.51	$1.20B	0.00%
EQRXEQRx, Inc.	$2.34	-2.09%	5.44	$1.14B	0.00%
ETHZEthzilla Corp.	$3.53	+0.00%	-0.17	$56.39M	0.00%
GRCLGracell Biotechnologies Inc.	$10.25	+0.05%	-1.55	$197.97M	0.00%

About CinCor Pharma, Inc.

CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.

CinCor Pharma, Inc. is headquartered in US.

CinCor Pharma, Inc. (CINC) stock trades at $29.06 with a market capitalization of $1.27B. The stock is valued at a price-to-earnings (P/E) ratio of -20.46, price-to-book of -16.15, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $10.53 and $43.15, and currently trades 32.7% below its 52-week high.

On profitability, CinCor Pharma, Inc. generates a return on equity (ROE) of 110.68% — well above the market average, a sign of a high-quality business, return on capital employed of -34.13%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cincor.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides